Braster SA
WSE:BRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Delivra Health Brands Inc
OTC:DHBUD
|
CA |
|
Vsee Health Inc
NASDAQ:VSEE
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| PL |
B
|
Braster SA
WSE:BRA
|
17m PLN |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
174.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
129.7B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.9B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
91.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.6B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.2B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.9B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.4B USD |
Loading...
|
Market Distribution
| Min | -535 500% |
| 30th Percentile | 18.1% |
| Median | 30.2% |
| 70th Percentile | 55.9% |
| Max | 807.1% |
Other Profitability Ratios
Braster SA
Glance View
Braster SA engages in the development and manufacturing of medical devices for self-examination. The firm provides research and development on breast cancer. The company applies liquid crystals and liquid crystal emulsion formula that is used to produce liquid crystal matrix based on LCD technology, continuous film CLCF (Continuous Liquid Crystal Film) in the diagnosis of breast cancer. Its main product is Braster Tester, which is a device that uses thermographic liquid crystal matrices for diagnosing breast cancer; the device is made up of three film matrices covered with a liquid crystal mixture that allows thermal imaging. The firm cooperates with the Jagiellonian University, with the participation of the clinical trial conducted by Thermacrac, among others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Braster SA is 93.7%, which is above its 3-year median of 80.6%.
Over the last 3 years, Braster SA’s Gross Margin has decreased from 148.8% to 93.7%. During this period, it reached a low of 57.7% on Jun 30, 2021 and a high of 148.8% on Mar 31, 2021.
